Gland Pharma Ltd
NSE :GLAND BSE :543245 Sector : PharmaceuticalsBuy, Sell or Hold GLAND? Ask The Analyst
BSE
prev close
OPEN PRICE
bid price (qty)
offer price (qty)
volume
Today's low / high
52 WK low / high
NSE
prev close
open price
bid price (qty)
offer price (qty)
volume
Today's' low / high
52 WK low / high
07 Nov 1803.80 (-2.83%) | 06 Nov 1856.35 (1.28%) | 05 Nov 1832.85 (13.78%) | 04 Nov 1610.90 (-2.15%) | 01 Nov 1646.35 (-0.29%) | 31 Oct 1651.10 (0.55%) | 30 Oct 1642.15 (1.03%) | 29 Oct 1625.40 (0.05%) | 28 Oct 1624.55 (1.16%) | 25 Oct 1605.85 (-2.20%) | 24 Oct 1641.95 (2.15%) | 23 Oct 1607.35 (-2.44%) | 22 Oct 1647.60 (-1.65%) | 21 Oct 1675.30 (1.53%) | 18 Oct 1650.10 (0.64%) | 17 Oct 1639.65 (-1.60%) | 16 Oct 1666.35 (1.00%) | 15 Oct 1649.85 (-1.86%) | 14 Oct 1681.15 (-1.02%) | 11 Oct 1698.55 (-0.23%) | 10 Oct 1702.50 (0.14%) |
Price Chart Historical Data Technical Chart
Technical Analysis
Short Term Investors
Very Bullish
Medium Term Investors
Neutral
Long Term Investors
Bearish
Moving Averages
5 DMA
Bullish
1749.64
10 DMA
Bullish
1689.87
20 DMA
Bullish
1672.88
50 DMA
Bullish
1766.45
100 DMA
Bearish
1857.21
200 DMA
Bearish
1842.44
Intraday Support and Resistance
(Based on Pivot Points) |
Updated On Nov 07, 2024 04:00 PM For Next Trading Session
Pivots | Classic | Fibonacci | Camarilla | Woodie | DM |
---|---|---|---|---|---|
R3 | 1893.76 | 1871.63 | 1819.21 | - | - |
R2 | 1871.63 | 1850.22 | 1814.08 | 1868.69 | - |
R1 | 1837.71 | 1836.99 | 1808.94 | 1831.83 | 1854.68 |
P | 1815.58 | 1815.58 | 1815.58 | 1812.64 | 1824.06 |
S1 | 1781.66 | 1794.17 | 1798.66 | 1775.78 | 1798.63 |
S2 | 1759.53 | 1780.94 | 1793.52 | 1756.59 | - |
S3 | 1725.61 | 1759.53 | 1788.39 | - | - |
Key Metrics
EPS
66.94
P/E
26.99
P/B
3.24
Dividend Yield
1.11%
Market Cap
29,718 Cr.
Face Value
1
Book Value
556.82
ROE
9.26%
EBITDA Growth
355.72 Cr.
Debt/Equity
0.02
Shareholding History
Quarterly Result (Figures in Rs. Crores)
Gland Pharma Ltd Quaterly Results
Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | |
INCOME | 1426.58 | 1582.55 | 1579.6 | 1453.14 | 1465.49 |
PROFIT | 194.08 | 191.86 | 192.42 | 143.76 | 163.53 |
EPS | 11.78 | 11.65 | 11.68 | 8.73 | 9.93 |
Gland Pharma Ltd Quaterly Results
Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | |
INCOME | 1051.78 | 1141.25 | 1221.79 | 1060.51 | 1120.79 |
PROFIT | 257.53 | 276.81 | 321.41 | 222.92 | 281.71 |
EPS | 15.64 | 16.81 | 19.51 | 13.53 | 17.1 |
Profit & Loss (Figures in Rs. Crores)
Gland Pharma Ltd Profit & Loss
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | ||
INCOME | 2779.31 | 3871.15 | 4587.96 | 3911.98 | 5707.07 | |
PROFIT | 759.87 | 996.94 | 1208.44 | 820.62 | 772.05 | |
EPS | 0 | 60.94 | 73.75 | 47.42 | 46.9 |
Gland Pharma Ltd Profit & Loss
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | ||
INCOME | 1017.07 | 1375.14 | 1466.37 | 1735.4 | 2243.91 | 2779.31 | 3871.15 | 4587.96 | 3903.91 | 4246.67 | |
PROFIT | 209.29 | 313.72 | 413.69 | 321.1 | 465.06 | 759.87 | 996.99 | 1208.94 | 815.38 | 1043.72 | |
EPS | 133.53 | 202.39 | 267.01 | 207.24 | 291.65 | 49.88 | 60.95 | 73.78 | 47.11 | 63.34 |
Balance Sheet (Figures in Rs. Crores)
Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | |
SOURCES OF FUNDS : | |||||
Share Capital | 16.47 | 16.47 | 16.43 | 16.36 | 15.5 |
Reserves Total | 8,707.37 | 7,942.25 | 7,141.11 | 5,886.88 | 3,630.74 |
Equity Application Money | 0 | 0 | 0.08 | 0 | 0 |
Total Shareholders Funds | 8,723.84 | 7,958.72 | 7,157.62 | 5,903.24 | 3,646.24 |
Unsecured Loans | 372.17 | 4.45 | 4.74 | 5 | 4.96 |
Total Debt | 372.17 | 4.45 | 4.74 | 5 | 4.96 |
Other Liabilities | 177.7 | 1.73 | 1.73 | 1.73 | 2.66 |
Total Liabilities | 9,273.71 | 7,964.9 | 7,164.09 | 5,909.97 | 3,653.86 |
APPLICATION OF FUNDS : | |||||
Gross Block | 5,011.68 | 2,294.96 | 2,081.32 | 1,430.7 | 1,347.81 |
Less: Accumulated Depreciation | 1,064.93 | 724.41 | 579.13 | 476.47 | 379.71 |
Net Block | 3,946.75 | 1,570.55 | 1,502.19 | 954.23 | 968.1 |
Capital Work in Progress | 237.88 | 177.22 | 190.75 | 337.81 | 188.47 |
Investments | 0 | 0 | 154.87 | 0 | 0 |
Inventories | 1,655.24 | 1,945.3 | 1,185.67 | 1,275.17 | 756.28 |
Sundry Debtors | 1,558.69 | 871.39 | 1,074.81 | 670.97 | 601.79 |
Cash and Bank Balance | 1,839.43 | 3,770.68 | 3,093.44 | 3,005.75 | 1,325.19 |
Loans and Advances | 591.79 | 313.44 | 343.3 | 171.75 | 163.03 |
Total Current Assets | 5,645.15 | 6,900.81 | 5,697.21 | 5,123.64 | 2,846.29 |
Current Liabilities | 1,056.87 | 696.12 | 539.02 | 458.41 | 329.93 |
Provisions | 110.54 | 32.3 | 42.75 | 53.82 | 28.2 |
Total Current Liabilities & Provisions | 1,167.42 | 728.42 | 581.77 | 512.23 | 358.13 |
Net Current Assets | 4,477.73 | 6,172.39 | 5,115.44 | 4,611.41 | 2,488.15 |
Deferred Tax Assets | 58.72 | 22.71 | 7.65 | 6.02 | 6.05 |
Deferred Tax Liability | 228.4 | 106.92 | 95.41 | 79.9 | 80.1 |
Net Deferred Tax | -169.68 | -84.21 | -87.76 | -73.88 | -74.05 |
Other Assets | 781.03 | 128.96 | 288.6 | 80.4 | 83.18 |
Total Assets | 9,273.71 | 7,964.9 | 7,164.09 | 5,909.97 | 3,653.85 |
Contingent Liabilities | 15.58 | 22.07 | 12.76 | 74.7 | 11.83 |
Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | |
SOURCES OF FUNDS : | ||||||||||
Share Capital | 16.47 | 16.47 | 16.43 | 16.36 | 15.5 | 15.5 | 15.5 | 15.5 | 15.49 | 15.67 |
Reserves Total | 8,978.82 | 7,936.83 | 7,141.72 | 5,886.93 | 3,630.74 | 2,846.62 | 2,394.93 | 2,074.32 | 1,661.57 | 1,378.52 |
Equity Application Money | 0 | 0 | 0.08 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Shareholders Funds | 8,995.29 | 7,953.3 | 7,158.23 | 5,903.29 | 3,646.24 | 2,862.12 | 2,410.43 | 2,089.82 | 1,677.06 | 1,394.19 |
Secured Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 90.07 | 129.01 |
Unsecured Loans | 3.66 | 4.45 | 4.74 | 5 | 4.96 | 5.49 | 5.92 | 6.38 | 26.97 | 37.45 |
Total Debt | 3.66 | 4.45 | 4.74 | 5 | 4.96 | 5.49 | 5.92 | 6.38 | 117.04 | 166.46 |
Other Liabilities | 20.69 | 1.73 | 1.73 | 1.73 | 2.66 | 15.2 | 38.13 | 39.26 | 0.37 | 0.27 |
Total Liabilities | 9,019.64 | 7,959.48 | 7,164.7 | 5,910.02 | 3,653.86 | 2,882.81 | 2,454.48 | 2,135.46 | 1,794.47 | 1,560.92 |
APPLICATION OF FUNDS : | ||||||||||
Gross Block | 2,579.91 | 2,294.96 | 2,081.32 | 1,430.7 | 1,347.81 | 1,219.58 | 1,054.45 | 1,005.52 | 1,020.22 | 820.49 |
Less : Accumulated Depreciation | 886.18 | 724.41 | 579.13 | 476.47 | 379.71 | 290.83 | 211.81 | 133.94 | 232.34 | 171.86 |
Net Block | 1,693.73 | 1,570.55 | 1,502.19 | 954.23 | 968.1 | 928.75 | 842.64 | 871.58 | 787.88 | 648.63 |
Capital Work in Progress | 120.01 | 177.22 | 190.75 | 337.81 | 188.47 | 123.16 | 198.88 | 161.15 | 202.1 | 192.08 |
Investments | 2,385.74 | 8.16 | 163.03 | 0.55 | 0 | 0 | 0 | 0 | 0.17 | 0.17 |
Inventories | 1,260.21 | 1,945.3 | 1,185.67 | 1,275.17 | 756.28 | 911.88 | 512.83 | 378.72 | 367.08 | 321.19 |
Sundry Debtors | 1,171.4 | 862.84 | 1,074.81 | 670.97 | 601.79 | 506.1 | 475.21 | 417.87 | 350.69 | 169.31 |
Cash and Bank Balance | 1,598.55 | 3,767 | 3,085.8 | 3,005.2 | 1,325.19 | 753.35 | 651.14 | 533.08 | 273.23 | 315.63 |
Loans and Advances | 541.17 | 313.2 | 343.3 | 171.73 | 163.03 | 186.14 | 211.8 | 78.48 | 80.91 | 49.35 |
Total Current Assets | 4,571.32 | 6,888.34 | 5,689.57 | 5,123.07 | 2,846.29 | 2,357.46 | 1,850.98 | 1,408.15 | 1,071.9 | 855.48 |
Current Liabilities | 381.12 | 698.17 | 538.93 | 458.34 | 329.93 | 518.27 | 363.11 | 250.7 | 219.68 | 154.38 |
Provisions | 32.07 | 31.32 | 42.75 | 53.82 | 28.2 | 13.89 | 15.01 | 2.23 | 7.12 | 0.5 |
Total Current Liabilities & Provisions | 413.19 | 729.49 | 581.68 | 512.16 | 358.13 | 532.15 | 378.12 | 252.93 | 226.8 | 154.89 |
Net Current Assets | 4,158.14 | 6,158.85 | 5,107.89 | 4,610.9 | 2,488.15 | 1,825.31 | 1,472.86 | 1,155.22 | 845.1 | 700.6 |
Deferred Tax Assets | 8.28 | 22.71 | 7.65 | 6.02 | 6.05 | 1.63 | 1.29 | 0.94 | 0 | 0.39 |
Deferred Tax Liability | 116.54 | 106.92 | 95.41 | 79.9 | 80.1 | 109.26 | 97.04 | 86.31 | 65.04 | 42.73 |
Net Deferred Tax | -108.26 | -84.21 | -87.76 | -73.88 | -74.05 | -107.63 | -95.75 | -85.37 | -65.04 | -42.34 |
Other Assets | 770.3 | 128.92 | 288.6 | 80.4 | 83.18 | 113.22 | 35.84 | 32.86 | 24.25 | 61.78 |
Total Assets | 9,019.65 | 7,959.48 | 7,164.7 | 5,910.01 | 3,653.85 | 2,882.81 | 2,454.47 | 2,135.44 | 1,794.46 | 1,560.91 |
Contingent Liabilities | 15.58 | 22.07 | 12.76 | 74.7 | 11.83 | 21.17 | 0 | 83.99 | 46.7 | 7.66 |
Cash Flow (Figures in Rs. Crores)
Net Profit before Tax and Extr... | 1,132.54 |
Depreciation | 344.57 |
Interest (Net) | -128.82 |
P/L on Sales of Assets | -0.25 |
Prov. and W/O (Net) | 21.42 |
P/L in Forex | -12.97 |
Total Adjustments (PBT and Ext... | 223.6 |
Operating Profit before Workin... | 1,356.15 |
Trade and 0ther Receivables | -324.96 |
Inventories | 666.08 |
Trade Payables | -378.87 |
Loans and Advances | -5.1 |
Total Adjustments (OP before W... | -53.2 |
Cash Generated from/(used in) ... | 1,302.95 |
Direct Taxes Paid | -306.15 |
Total Adjustments(Cash Generat... | -306.15 |
Cash Flow before Extraordinary... | 996.8 |
Net Cash from Operating Activi... | 996.8 |
Purchased of Fixed Assets | -398.26 |
Sale of Fixed Assets | 0.77 |
Purchase of Investments | -264.99 |
Sale of Investments | 265.34 |
Interest Received | 137.05 |
Acquisition of Companies | -1,021.76 |
Net Cash used in Investing Act... | -1,749.19 |
Proceeds from Issue of shares ... | 0.53 |
Proceed from 0ther Long Term B... | 21.03 |
Of the Long Tem Borrowings | -777.31 |
Of Financial Liabilities | -18.05 |
Interest Paid | -25.61 |
Net Cash used in Financing Act... | -799.42 |
Net Profit before Tax and Extr... | 1,405.5 |
Depreciation | 162.11 |
Interest (Net) | -142.37 |
P/L on Sales of Assets | 0.88 |
P/L on Sales of Invest | -0.35 |
Prov. and W/O (Net) | 11.74 |
P/L in Forex | -8.85 |
Total Adjustments (PBT and Ext... | 23.15 |
Operating Profit before Workin... | 1,428.65 |
Trade and 0ther Receivables | -317.53 |
Inventories | 685.09 |
Trade Payables | -296.85 |
Loans and Advances | -24.22 |
Total Adjustments (OP before W... | 23.38 |
Cash Generated from/(used in) ... | 1,452.02 |
Direct Taxes Paid | -316.05 |
Total Adjustments(Cash Generat... | -316.05 |
Cash Flow before Extraordinary... | 1,135.97 |
Net Cash from Operating Activi... | 1,135.97 |
Purchased of Fixed Assets | -236.92 |
Sale of Fixed Assets | 0.15 |
Purchase of Investments | -264.99 |
Sale of Investments | 265.34 |
Interest Received | 165.14 |
Invest.In Subsidiaires | -2,377.58 |
Net Cash used in Investing Act... | -2,917.58 |
Proceeds from Issue of shares ... | 0.53 |
Of the Long Tem Borrowings | -0.56 |
Of Financial Liabilities | -0.23 |
Interest Paid | -7.14 |
Net Cash used in Financing Act... | -7.4 |
Company Details
Registered Office |
|
Address | Sy No 143-148 150&151 Nr Gandi, X Roads D P Pally Dundigal |
City | Hyderabad |
State | Telangana |
Pin Code | 500043 |
Tel. No. | 91-40-30510999 |
Fax. No. | 91-40-30510800 |
investors@glandpharma.com | |
Internet | http://www.glandpharma.com |
Registrars |
|
Address | Sy No 143-148 150&151 Nr Gandi |
City | Hyderabad |
State | Telangana |
Pin Code | 500043 |
Tel. No. | 91-40-30510999 |
Fax. No. | 91-40-30510800 |
investors@glandpharma.com | |
Internet | http://www.glandpharma.com |
Management |
|
Name | Designation |
Yiu Kwan Stanley Lau | Chairman & Independent Directo |
SRINIVAS SADU | Managing Director & CEO |
UDO JAHANNES VETTER | Non-Exec & Non-Independent Dir |
C S N Murthy | Independent Director |
ESSAJI GOOLAM VAHANVATI | Independent Director |
Naina Lal Kidwai | Independent Director |
Jia Ai (Allen) Zhang | Non-Exec & Non-Independent Dir |
Wenjie Zhang | Non Executive Director |
Wei Huang | Additional Director |